Aquestive Therapeutics, Inc. AQST License and royalty revenue a — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aquestive Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Aquestive Therapeutics, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aquestive Therapeutics, Inc.'s license and royalty revenue a — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Aquestive Therapeutics, Inc.'s license and royalty revenue a — revenue?
- Aquestive Therapeutics, Inc. (AQST) reported license and royalty revenue a — revenue of $500K in Q2 2026.
- How has Aquestive Therapeutics, Inc.'s license and royalty revenue a — revenue changed year-over-year?
- Aquestive Therapeutics, Inc.'s license and royalty revenue a — revenue decreased by 40.4% year-over-year, from $839K to $500K.
- What is the long-term trend for Aquestive Therapeutics, Inc.'s license and royalty revenue a — revenue?
- Over 4 years (2021 to 2025), Aquestive Therapeutics, Inc.'s license and royalty revenue a — revenue has grown at a -14.9% compound annual growth rate (CAGR), from $6.71M to $3.52M.
- What does license and royalty revenue a — revenue mean?
- This metric represents the total revenue recognized from licensing intellectual property and royalty payments received from third-party partners for the commercialization of the company's proprietary pharmaceutical technologies. It reflects the monetization of the company's R&D efforts through external partnerships rather than direct product sales. This stream is a key indicator of the company's ability to generate recurring, high-margin cash flow from its technology platform and patent portfolio.